ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 95.86 |
| Open | 96.19 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 94.59 - 97.11 |
| 52 Week Range | 51.33 - 153.99 |
| Volume | 843,444 |
| Avg. Volume | 1,003,841 |
| Market Cap | 9.489B |
| Beta | 3.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.42 |
| Earnings Date | May 3, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 155.59 |
- Business Wire•21 hours ago
Alnylam Reports New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the American Academy of Neurology 2018 Annual Meeting
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, today announced new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, at the American Academy of Neurology (AAN) 2018 Annual Meeting, being held April 21-27, 2018 in Los Angeles, California. To that end, we are pleased to share these new results from the APOLLO study, including a post-hoc, exploratory analysis demonstrating a significant decrease in the composite rate of all-cause hospitalization and mortality in patients receiving patisiran compared to placebo.
- Business Wire•2 days ago
Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that the European Medicines Agency Committee for Orphan Medicinal Products has issued a positive opinion recommending ALN-TTRsc02, an investigational, subcutaneously administered RNAi therapeutic, for designation as an orphan medicinal product for the treatment of transthyretin -mediated amyloidosis.
- Motley Fool•4 days ago
Why Dicerna Rocketed Higher Today
Investors are happy the biotech ended a lawsuit hanging over its head.
American City Business Journals•5 days agoDicerna to pay $27M to settle Alnylam trade secrets lawsuit
The Cambridge biotechs are both developing RNA interference drugs, which are designed to silence disease-causing genes.
- Reuters•5 days ago
U.S. biotech companies Alnylam, Dicerna settle trade secrets case
Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.
- Reuters•5 days ago
U.S. biotech companies Alnylam, Dicerna settle trade secrets case
Alnylam Pharmaceuticals Inc said on Friday that Dicerna Pharmaceuticals Inc will pay it $25 million in cash and stock to resolve a lawsuit claiming it stole trade secrets about gene-silencing technology used to develop drug treatments. The settlement between the two biotech companies resolves a lawsuit that Alnylam filed against Dicerna in 2015. Under the agreement, Dicerna said it will pay Alnylam $2 million up-front plus 983,208 shares of its common stock.
- Business Wire•5 days ago
Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending Litigation
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced that it has entered into a settlement agreement with Dicerna Pharmaceuticals resolving trade secret misappropriation claims against Dicerna, and counterclaims asserted by Dicerna, in pending litigation in the Superior Court of Middlesex County, Massachusetts.
- Zacks•7 days ago
Alnylam (ALNY) Reports Positive Data for RNAi Candidate
Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of acute hepatic porphyrias.
- Business Wire•11 days ago
Alnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced new results from the Phase 1 and Phase 1/2 open-label extension studies of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias .
Markit•12 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ALNY totaled $105 million.
Market Realist•13 days agoJakafi Continues to Be Strong Growth Driver for Incyte in 2018
Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.
Market Realist•14 days agoWhy CASI Pharmaceuticals Stock Rose Last Week
On Monday, April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6. Its 52-week low was $0.91 on June 20, 2017.
Markit•15 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
- Forbes•15 days ago
A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star
Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.
- Benzinga•19 days ago
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Here's a few must-watch biotech catalysts this week . Conferences Panamerican League of Associations for Rheumatology Congress – April 7-11 at Hotel Hilton, Buenos Aires, Argentina. The International Liver ...
Markit•19 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
- Motley Fool•21 days ago
How Worried Should Alnylam and Ionis Really Be About Pfizer's New Data?
A battle for transthyretin amyloidosis patients is brewing.
Market Realist•22 days agoWhy Did Regeneron Pharmaceuticals’ Stock Price Rise Last Week?
On March 28, 2018, Regeneron Pharmaceuticals (REGN) was trading at $344.36, a ~9.8% rise from its 52-week low of $313.53. On March 29, Regeneron stock closed at $344.36, which represented a ~7.2% rise from its share price in the week ended March 23, 2017. On March 21, 2018, Regeneron Pharmaceuticals announced a collaboration agreement with Alnylam Pharmaceuticals (ALNY) for the identification of RNA interference therapeutics for the treatment of chronic liver disease NASH (non-alcoholic steatohepatitis) and other related diseases.
- Market Exclusive•22 days ago
Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc
Zosano Pharma Corporation (NASDAQ:ZSAN) was a real end of the week mover in the biotechnology sector last week, with the company sliding close to 45% on the news that it is set to conduct an underwritten public offering. The public offering will see Zosano issue 10 million shares at an average price of five dollars […] The post Here’s What Just Happened With Zosano Pharma Corporation And Pfizer Inc appeared first on Market Exclusive.
- Market Realist•22 days ago
Analysts’ Recommendations for United Therapeutics in March 2018
A Look into the Performance of United Therapeutics in 2017
Market Realist•22 days agoHow Did United Therapeutics Perform in 4Q17 and Fiscal 2017?
A Look into the Performance of United Therapeutics in 2017United Therapeutics’ revenue trends
- Zacks•22 days ago
Alnylam Falls on Pfizer's Rare Disease Drug Success
Shares of Alnylam (ALNY) fall by more than 8% after Pfizer reports top-line results from the phase III study of tafamidis.
- Investor's Business Daily•22 days ago
How Pfizer Sneaked Into Rare-Disease Market And Hit Alnylam, Ionis
Alnylam and Ionis stocks fell Monday after Dow Jones component Pfizer announced strong results for a competing rare-disease drug.
- Benzinga•23 days ago
With Alnylam Pharma Down More Than 15%, Analyst Says Buy The Dip
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) continued to decline after Pfizer Inc. (NYSE: PFE ) reported its transthyretin stabilizer Vyndaqel met primary Phase 3 endpoints Thursday. However, B Riley ...
- Benzinga•23 days ago
Benzinga's Top Analyst Calls From April 2, 2018
These headlines first appeared on Benzinga Pro . Stifel on Walmart Inc (NYSE: WMT ), Humana Inc (NYSE: HUM ) WSJ report: Expansion of an existing prescription drug plan partnership 'is most likely,' would ...
